The leukemic oncogene EVI1 hijacks a MYC super-enhancer by CTCF-facilitated loops.


Journal

Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555

Informations de publication

Date de publication:
28 09 2021
Historique:
received: 10 06 2021
accepted: 02 09 2021
entrez: 29 9 2021
pubmed: 30 9 2021
medline: 26 10 2021
Statut: epublish

Résumé

Chromosomal rearrangements are a frequent cause of oncogene deregulation in human malignancies. Overexpression of EVI1 is found in a subgroup of acute myeloid leukemia (AML) with 3q26 chromosomal rearrangements, which is often therapy resistant. In AMLs harboring a t(3;8)(q26;q24), we observed the translocation of a MYC super-enhancer (MYC SE) to the EVI1 locus. We generated an in vitro model mimicking a patient-based t(3;8)(q26;q24) using CRISPR-Cas9 technology and demonstrated hyperactivation of EVI1 by the hijacked MYC SE. This MYC SE contains multiple enhancer modules, of which only one recruits transcription factors active in early hematopoiesis. This enhancer module is critical for EVI1 overexpression as well as enhancer-promoter interaction. Multiple CTCF binding regions in the MYC SE facilitate this enhancer-promoter interaction, which also involves a CTCF binding site upstream of the EVI1 promoter. We hypothesize that this CTCF site acts as an enhancer-docking site in t(3;8) AML. Genomic analyses of other 3q26-rearranged AML patient cells point to a common mechanism by which EVI1 uses this docking site to hijack enhancers active in early hematopoiesis.

Identifiants

pubmed: 34584081
doi: 10.1038/s41467-021-25862-3
pii: 10.1038/s41467-021-25862-3
pmc: PMC8479123
doi:

Substances chimiques

CCCTC-Binding Factor 0
MDS1 and EVI1 Complex Locus Protein 0
MECOM protein, human 0
Proto-Oncogene Proteins c-myc 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

5679

Informations de copyright

© 2021. The Author(s).

Références

Stadhouders, R., Filion, G. J. & Graf, T. Transcription factors and 3D genome conformation in cell-fate decisions. Nature 569, 345–354 (2019).
pubmed: 31092938 doi: 10.1038/s41586-019-1182-7
Dixon, J. R. et al. Topological domains in mammalian genomes identified by analysis of chromatin interactions. Nature 485, 376–380 (2012).
pubmed: 22495300 pmcid: 3356448 doi: 10.1038/nature11082
Rao, S. S. et al. A 3D map of the human genome at kilobase resolution reveals principles of chromatin looping. Cell 159, 1665–1680 (2014).
pubmed: 25497547 pmcid: 5635824 doi: 10.1016/j.cell.2014.11.021
Dowen, J. M. et al. Control of cell identity genes occurs in insulated neighborhoods in mammalian chromosomes. Cell 159, 374–387 (2014).
pubmed: 25303531 pmcid: 4197132 doi: 10.1016/j.cell.2014.09.030
Zuin, J. et al. Cohesin and CTCF differentially affect chromatin architecture and gene expression in human cells. Proc. Natl Acad. Sci. USA 111, 996–1001 (2014).
pubmed: 24335803 doi: 10.1073/pnas.1317788111
Schuijers, J. et al. Transcriptional dysregulation of MYC reveals common enhancer-docking mechanism. Cell Rep. 23, 349–360 (2018).
pubmed: 29641996 pmcid: 5929158 doi: 10.1016/j.celrep.2018.03.056
Huang, J. et al. Dissecting super-enhancer hierarchy based on chromatin interactions. Nat. Commun. 9, 943 (2018).
pubmed: 29507293 pmcid: 5838163 doi: 10.1038/s41467-018-03279-9
Weintraub, A. S. et al. YY1 is a structural regulator of enhancer-promoter loops. Cell 171, 1573–1588 e1528 (2017).
pubmed: 29224777 pmcid: 5785279 doi: 10.1016/j.cell.2017.11.008
Bulger, M. & Groudine, M. Functional and mechanistic diversity of distal transcription enhancers. Cell 144, 327–339 (2011).
pubmed: 21295696 pmcid: 3742076 doi: 10.1016/j.cell.2011.01.024
Spitz, F. Gene regulation at a distance: from remote enhancers to 3D regulatory ensembles. Semin Cell Dev. Biol. 57, 57–67 (2016).
pubmed: 27364700 doi: 10.1016/j.semcdb.2016.06.017
Muerdter, F. & Stark, A. Gene regulation: activation through space. Curr. Biol. 26, R895–R898 (2016).
pubmed: 27728794 doi: 10.1016/j.cub.2016.08.031
Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646–674 (2011).
pubmed: 21376230 doi: 10.1016/j.cell.2011.02.013
Mitelman, F., Johansson, B. & Mertens, F. The impact of translocations and gene fusions on cancer causation. Nat. Rev. Cancer 7, 233–245 (2007).
pubmed: 17361217 doi: 10.1038/nrc2091
Yamazaki, H. et al. A remote GATA2 hematopoietic enhancer drives leukemogenesis in inv(3)(q21;q26) by activating EVI1 expression. Cancer Cell 25, 415–427 (2014).
pubmed: 24703906 pmcid: 4012341 doi: 10.1016/j.ccr.2014.02.008
Groschel, S. et al. A single oncogenic enhancer rearrangement causes concomitant EVI1 and GATA2 deregulation in leukemia. Cell 157, 369–381 (2014).
pubmed: 24703711 doi: 10.1016/j.cell.2014.02.019
Lugthart, S. et al. High EVI1 levels predict adverse outcome in acute myeloid leukemia: prevalence of EVI1 overexpression and chromosome 3q26 abnormalities underestimated. Blood 111, 4329–4337 (2008).
pubmed: 18272813 doi: 10.1182/blood-2007-10-119230
Gröschel, S. et al. High EVI1 expression predicts outcome in younger adult patients with acute myeloid leukemia and is associated with distinct cytogenetic abnormalities. J. Clin. Oncol. 28, 2101–2107 (2010).
pubmed: 20308656 doi: 10.1200/JCO.2009.26.0646
Lugthart, S. et al. Clinical, molecular, and prognostic significance of WHO type inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and various other 3q abnormalities in acute myeloid leukemia. J. Clin. Oncol. 28, 3890–3898 (2010).
pubmed: 20660833 doi: 10.1200/JCO.2010.29.2771
Barjesteh van Waalwijk van Doorn-Khosrovani, S. et al. High EVI1 expression predicts poor survival in acute myeloid leukemia: a study of 319 de novo AML patients. Blood 101, 837–845 (2003).
pubmed: 12393383 doi: 10.1182/blood-2002-05-1459
Ottema, S. et al. Atypical 3q26/MECOM rearrangements genocopy inv(3)/t(3;3) in acute myeloid leukemia. Blood 136, 224–234 (2020).
pubmed: 32219447 doi: 10.1182/blood.2019003701
Lin, P., Medeiros, L. J., Yin, C. C. & Abruzzo, L. V. Translocation (3;8)(q26;q24): a recurrent chromosomal abnormality in myelodysplastic syndrome and acute myeloid leukemia. Cancer Genet. Cytogenet. 166, 82–85 (2006).
pubmed: 16616115 doi: 10.1016/j.cancergencyto.2005.10.007
Lennon, P. A. et al. Aberrant EVI1 expression in acute myeloid leukemias associated with the t(3;8)(q26;q24). Cancer Genet. Cytogenet. 177, 37–42 (2007).
pubmed: 17693189 doi: 10.1016/j.cancergencyto.2007.05.007
De Braekeleer, M. et al. Breakpoint heterogeneity in (2;3)(p15–23;q26) translocations involving EVI1 in myeloid hemopathies. Blood Cells Molecules Dis. 54, 160–163 (2015).
doi: 10.1016/j.bcmd.2014.11.015
Trubia, M. et al. Characterization of a recurrent translocation t(2;3)(p15–22;q26) occurring in acute myeloid leukaemia. Leukemia 20, 48–54 (2006).
pubmed: 16619048 doi: 10.1038/sj.leu.2404020
Storlazzi, C. T. et al. A novel chromosomal translocation t(3;7)(q26;q21) in myeloid leukemia resulting in overexpression of EVI1. Ann. Hematol. 83, 78–83 (2004).
pubmed: 14551738 doi: 10.1007/s00277-003-0778-y
Nucifora, G., Laricchia-Robbio, L. & Senyuk, V. EVI1 and hematopoietic disorders: History and perspectives. Gene 368, 1–11 (2006).
pubmed: 16314052 doi: 10.1016/j.gene.2005.09.020
Tang, G. et al. t(3;8)(q26.2;q24) often leads to MECOM/MYC rearrangement and is commonly associated with therapy-related myeloid neoplasms and/or disease progression. J. Mol. Diagn. 21, 343–351 (2019).
pubmed: 30576868 doi: 10.1016/j.jmoldx.2018.10.005
Bahr, C. et al. A Myc enhancer cluster regulates normal and leukaemic haematopoietic stem cell hierarchies. Nature 553, 515–520 (2018).
pubmed: 29342133 doi: 10.1038/nature25193
Beck, D. et al. Genome-wide analysis of transcriptional regulators in human HSPCs reveals a densely interconnected network of coding and noncoding genes. Blood 122, e12–e22 (2013).
pubmed: 23974199 doi: 10.1182/blood-2013-03-490425
Fernandez, J. M. et al. The BLUEPRINT data analysis portal. Cell Syst. 3, 491–495 e495 (2016).
pubmed: 27863955 pmcid: 5919098 doi: 10.1016/j.cels.2016.10.021
Smeenk, L. et al. Selective requirement of MYB for oncogenic hyperactivation of a translocated enhancer in leukemia. Cancer Discov. https://doi.org/10.1158/2159-8290.CD-20-1793 (2021).
Valk, P. J. M. et al. Prognostically useful gene-expression profiles in acute myeloid leukemia. N. Engl. J. Med. 350, 1617–1628 (2004).
pubmed: 15084694 doi: 10.1056/NEJMoa040465
Denholtz, M. & Plath, K. Pluripotency in 3D: genome organization in pluripotent cells. Curr. Opin. Cell Biol. 24, 793–801 (2012).
pubmed: 23199754 pmcid: 3540188 doi: 10.1016/j.ceb.2012.11.001
Aranda-Orgilles, B. et al. MED12 regulates HSC-specific enhancers independently of mediator kinase activity to control hematopoiesis. Cell Stem Cell 19, 784–799 (2016).
pubmed: 27570068 pmcid: 5268820 doi: 10.1016/j.stem.2016.08.004
Kubo, N. et al. Promoter-proximal CTCF binding promotes distal enhancer-dependent gene activation. Nat. Struct. Mol. Biol. 28, 152–161 (2021).
pubmed: 33398174 pmcid: 7913465 doi: 10.1038/s41594-020-00539-5
Labun, K. et al. CHOPCHOP v3: expanding the CRISPR web toolbox beyond genome editing. Nucleic Acids Res. 47, W171–W174 (2019).
pubmed: 31106371 pmcid: 6602426 doi: 10.1093/nar/gkz365
International Standing Committee on Human Cytogenomic Nomenclature, McGowan-Jordan, J., Simons, A. & Schmid, M. ISCN: an International System for Human Cytogenomic Nomenclature (2016).
Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 25, 1754–1760 (2009).
pubmed: 19451168 pmcid: 2705234 doi: 10.1093/bioinformatics/btp324
Chen, K. et al. BreakDancer: an algorithm for high-resolution mapping of genomic structural variation. Nat. Methods 6, 677–681 (2009).
pubmed: 19668202 pmcid: 3661775 doi: 10.1038/nmeth.1363
Livak, K. J. & Schmittgen, T. D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25, 402–408 (2001).
pubmed: 11846609 doi: 10.1006/meth.2001.1262
Mulet-Lazaro, R. et al. Allele-specific expression of GATA2 due to epigenetic dysregulation in CEBPA double mutant AML. Blood https://doi.org/10.1182/blood.2020009244 (2021).
Patro, R., Duggal, G., Love, M. I., Irizarry, R. A. & Kingsford, C. Salmon provides fast and bias-aware quantification of transcript expression. Nat. Methods 14, 417–419 (2017).
pubmed: 28263959 pmcid: 5600148 doi: 10.1038/nmeth.4197
Soneson, C., Love, M. I. & Robinson, M. D. Differential analyses for RNA-seq: transcript-level estimates improve gene-level inferences. F1000Res 4, 1521 (2015).
pubmed: 26925227 doi: 10.12688/f1000research.7563.1
Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).
pubmed: 25516281 pmcid: 4302049 doi: 10.1186/s13059-014-0550-8
Ziebarth, J. D., Bhattacharya, A. & Cui, Y. CTCFBSDB 2.0: a database for CTCF-binding sites and genome organization. Nucleic Acids Res. 41, D188–D194 (2013).
pubmed: 23193294 doi: 10.1093/nar/gks1165
Fornes, O. et al. JASPAR 2020: update of the open-access database of transcription factor binding profiles. Nucleic Acids Res. 48, D87–D92 (2020).
pubmed: 31701148
Krueger, F., James, F., Ewels, P., Afyounian, E. & Schuster-Boeckler, B. FelixKrueger/TrimGalore: v0.6.7 - DOI via Zenodo (0.6.7). Zenodo. https://doi.org/10.5281/zenodo.5127899 (2021).
Bushnell, B. BBMap: A Fast, Accurate, Splice-Aware Aligner. (2014).
Clement, K. et al. CRISPResso2 provides accurate and rapid genome editing sequence analysis. Nat. Biotechnol. 37, 224–226 (2019).
pubmed: 30809026 pmcid: 6533916 doi: 10.1038/s41587-019-0032-3
van de Werken, H. J. et al. Robust 4C-seq data analysis to screen for regulatory DNA interactions. Nat. Methods 9, 969–972 (2012).
pubmed: 22961246 doi: 10.1038/nmeth.2173
Krijger, P. H. L., Geeven, G., Bianchi, V., Hilvering, C. R. E. & de Laat, W. 4C-seq from beginning to end: a detailed protocol for sample preparation and data analysis. Methods 170, 17–32 (2020).
pubmed: 31351925 doi: 10.1016/j.ymeth.2019.07.014
Langmead, B. Aligning short sequencing reads with Bowtie. Curr. Protoc. Bioinform. 11, 17 (2010).
Robinson, J. T. et al. Integrative genomics viewer. Nat. Biotechnol. 29, 24–26 (2011).
pubmed: 21221095 pmcid: 3346182 doi: 10.1038/nbt.1754
Ramirez, F. et al. deepTools2: a next generation web server for deep-sequencing data analysis. Nucleic Acids Res. 44, W160–W165 (2016).
pubmed: 27079975 pmcid: 4987876 doi: 10.1093/nar/gkw257
Zhang, Y. et al. Model-based analysis of ChIP-Seq (MACS). Genome Biol. 9, R137–R137 (2008).
pubmed: 18798982 pmcid: 2592715 doi: 10.1186/gb-2008-9-9-r137
Encode Project Consortium. An integrated encyclopedia of DNA elements in the human genome. Nature 489, 57–74 (2012).
doi: 10.1038/nature11247
Langmead, B. & Salzberg, S. L. Fast gapped-read alignment with Bowtie 2. Nat. Methods 9, 357–359 (2012).
pubmed: 22388286 pmcid: 3322381 doi: 10.1038/nmeth.1923
Kuhn, R. M., Haussler, D. & Kent, W. J. The UCSC genome browser and associated tools. Brief. Bioinform. 14, 144–161 (2013).
pubmed: 22908213 doi: 10.1093/bib/bbs038
Liao, Y., Smyth, G. K. & Shi, W. featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics 30, 923–930 (2014).
pubmed: 24227677 doi: 10.1093/bioinformatics/btt656
Srebniak, M. et al. Application of SNP array for rapid prenatal diagnosis: implementation, genetic counselling and diagnostic flow. Eur. J. Hum. Genet. 19, 1230 (2011).
pubmed: 21694736 pmcid: 3230359 doi: 10.1038/ejhg.2011.119
Srebniak, M. I. et al. Prenatal SNP array testing in 1000 fetuses with ultrasound anomalies: causative, unexpected and susceptibility CNVs. Eur. J. Hum. Genet. 24, 645 (2015).
pubmed: 26328504 pmcid: 4930096 doi: 10.1038/ejhg.2015.193
Davis, C. A. et al. The encyclopedia of DNA elements (ENCODE): data portal update. Nucleic Acids Res. 46, D794–D801 (2018).
pubmed: 29126249 doi: 10.1093/nar/gkx1081
Fornes, O. et al. JASPAR 2020: update of the open-access database of transcription factor binding profiles. Nucleic Acids Res. 48, D87–D92 (2019).
pmcid: 7145627

Auteurs

Sophie Ottema (S)

Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
Oncode Institute, Utrecht, The Netherlands.

Roger Mulet-Lazaro (R)

Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
Oncode Institute, Utrecht, The Netherlands.

Claudia Erpelinck-Verschueren (C)

Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
Oncode Institute, Utrecht, The Netherlands.

Stanley van Herk (S)

Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
Oncode Institute, Utrecht, The Netherlands.

Marije Havermans (M)

Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
Oncode Institute, Utrecht, The Netherlands.

Andrea Arricibita Varea (A)

Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
Oncode Institute, Utrecht, The Netherlands.

Michael Vermeulen (M)

Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.

H Berna Beverloo (HB)

Department of Clinical Genetics, Erasmus University Medical Center, Rotterdam, The Netherlands.

Stefan Gröschel (S)

A380, German Cancer Research Center, Heidelberg, Germany.
Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany.

Torsten Haferlach (T)

Munich Leukemia Laboratory, Munich, Germany.

Claudia Haferlach (C)

Munich Leukemia Laboratory, Munich, Germany.

Bas J Wouters (B)

Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
Oncode Institute, Utrecht, The Netherlands.

Eric Bindels (E)

Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.

Leonie Smeenk (L)

Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
Oncode Institute, Utrecht, The Netherlands.

Ruud Delwel (R)

Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands. h.delwel@erasmusmc.nl.
Oncode Institute, Utrecht, The Netherlands. h.delwel@erasmusmc.nl.

Articles similaires

Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH